Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H17NO5 |
Molecular Weight | 327.3313 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(\C=C\C(=O)NC2=C(C=CC=C2)C(O)=O)C=C1OC
InChI
InChIKey=NZHGWWWHIYHZNX-CSKARUKUSA-N
InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
DescriptionSources: https://www.drugbank.ca/drugs/DB07615Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22753703
http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2185
Sources: https://www.drugbank.ca/drugs/DB07615
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22753703
http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2185
Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. Tranilast is used for the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23679559
Curator's Comment: Oral administration of tranilast inhibited the growth of rat gliomas in vivo, suggesting tranilast can cross the blood–brain barrier, tranilast has been patented for treating Alzheimer's disease
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P15691 Gene ID: 281572.0 Gene Symbol: VEGFA Target Organism: Bos taurus (Bovine) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10385256 |
22.0 µM [IC50] | ||
Target ID: GO:1990874 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10082476 |
100.0 µM [IC50] | ||
Target ID: Human dermal microvascular endothelial cells proliferation Sources: https://www.ncbi.nlm.nih.gov/pubmed/9401770 |
136.0 µM [IC50] | ||
Target ID: WP303 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2475113 |
0.1 mM [IC50] | ||
Target ID: GO:0019370 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6194082 |
110.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | RIZABEN Approved UseRIZABEN is used to treat bronchial asthma, allergic rhinitis, atopic dermatitis, keloid or hyperplastic scar. Launch Date1981 |
|||
Primary | RIZABEN Approved UseRIZABEN is used to treat bronchial asthma, allergic rhinitis, atopic dermatitis, keloid or hyperplastic scar. Launch Date1981 |
|||
Primary | RIZABEN Approved UseRIZABEN is used to treat bronchial asthma, allergic rhinitis, atopic dermatitis, keloid or hyperplastic scar. Launch Date1992 |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b] quinazoline-2-carboxylic acid on immediate allergic reactions. | 1986 Nov |
|
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1. | 2013 Sep 5 |
|
Omeprazole Inhibits Pancreatic Cancer Cell Invasion through a Nongenomic Aryl Hydrocarbon Receptor Pathway. | 2015 May 18 |
Sample Use Guides
In general, for dosage regimen: For adults, take 1 capsule (100 mg of the active ingredient) at a time, 3 times a day. The dosage should be adjusted according to the disease, age or symptoms.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2475113
Tranilast suppressed the production of PGD2 in a dose-dependent manner with an IC50 of 0.1 mM in rat peritoneal mast cells. The glutathione-dependent conversion of [14C]PGH2 to PGD2 by PGD synthetase (PGH-D isomerase, EC 5.3.99.2) was inhibited by Tranilast, with 50% inhibition achieved at 0.08 mM in broken cell preparations of rat peritoneal mast cells.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/10/756
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
||
|
FDA ORPHAN DRUG |
176803
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
||
|
NCI_THESAURUS |
C574
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
||
|
FDA ORPHAN DRUG |
311810
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
57330
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | RxNorm | ||
|
C012293
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
DB07615
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL415324
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
5070
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
Tranilast
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
5282230
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
DTXSID7023693
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
77572
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
C152712
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
758970
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
6326
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
53902-12-8
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
100000077473
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
m11001
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
2714
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
W-116
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
SUB11215MIG
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY | |||
|
HVF50SMY6E
Created by
admin on Fri Dec 15 15:24:58 GMT 2023 , Edited by admin on Fri Dec 15 15:24:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY